



**For further information please contact:**

**Cellzome AG**  
Tim Edwards  
Chief Executive Officer  
Tel: +49-6221-137 57-100  
press@cellzome.com

**Hogarth Partnership**  
Melanie Toyne-Sewell / John Olsen  
Tel: +44 (0) 207 357 9477

## Press Release

### Cellzome Concludes Collaboration with Bayer HealthCare

**Boston, USA, 6 September 2005** – Cellzome Inc. announces the successful completion of a collaboration on active compound profiling with Bayer HealthCare. The 15 month collaboration utilised Cellzome's chemical proteomics technology for the profiling of Bayer compounds in a variety of disease areas. Cellzome applied its technology both toward the generation of target hypotheses and for assessment of the binding selectivity of some active compounds identified at Bayer.

Dr. Hans-Joachim Zeiler, Vice President of Innovation Management at Bayer HealthCare said: "Cellzome has been an excellent partner to have on this collaboration, with good technology and a dedicated team on board."

Dr. Peter Rae, Senior Research Fellow at Bayer added: "Cellzome's ability to profile compounds against the proteome of a cell or tissue is useful in assessing specificity of protein binding. Cellzome's technology afforded us a good view of binding selectivities of compounds directed against various members of a large target class."

Tim Edwards, Cellzome's CEO, said:

"We have enjoyed working with the team at Bayer, and are pleased that one of our first collaborations has worked well for our partner. We appreciate Bayer's positive evaluation of our chemical proteomics technology."

#### **About Cellzome Inc.**

Cellzome is a drug discovery company with world-class, proprietary proteomics technology for target and lead identification, and a drug discovery program in Alzheimer's disease. The technology provides molecular understanding of disease and helps to identify the role of active compounds and their possible side effects, and thus provides insight into how potential drugs might behave in man.

Cellzome's strategy is to commercialise its technology through building its own pipeline of clinical products and through collaboration with leading pharmaceutical partners. To date it has signed such collaborations with Bayer HealthCare, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a large pan-therapeutic collaboration with Novartis and, in March 2005, a drug discovery collaboration in Alzheimer's disease with Ortho-McNeil Pharmaceutical and J&JPRD.

Cellzome is domiciled in the USA and employs about 75 people at its facilities in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com).

#### **About Bayer HealthCare AG**

Bayer HealthCare AG, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro.

The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004.

Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases. For more information, please visit the website: [www.bayerhealthcare.com](http://www.bayerhealthcare.com).